Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Optimizing myeloma treatment for frail patients: dosing, scheduling and administration

Clark DuMontier • 22 Sep 2023
IMS 2023
Multiple Myeloma Bortezomib Lenalidomide

Clark DuMontier, MD, MPH, VA Boston Healthcare System, Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, discusses dosing, scheduling, and the route of administration of multiple myeloma treatment in elderly and frail patients. His insights underscore the crucial balance between disease control and the preservation of quality of life (QoL). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Clark DuMontier

3:46
The current landscape of treatment for frail myeloma patients at relapse & challenges in this space
Clark DuMontier • 22 Sep 2023
9:11
Treatment intensity in frail patients with newly diagnosed multiple myeloma: VRd vs Rd
Clark DuMontier • 22 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals